Conclusion of the OptiSpheres 3 program

Quebec City, July 15, 2021 - Pharma in silica announces the conclusion of the research program OptiSpheres 3.

The development of two original biodistribution assays in mouse models and the development of the second-generation prototype of OpPacli™ (optimized paclitaxel) prototype are among the main results of the program.

The work was carried out in collaboration with SiliCycle chemists and the teams of Professors Nicolas Bertrand and Marc-André Fortin of the CHU de Québec/Université Laval.